-
-
-
-
-
-
-
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
-
-
-
-
-
-
-
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
-
-
-
-
-
-
-
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Announces FDA Acceptance of sNDA for DEXTENZA for Treatment of Ocular Itching Associated with Allergic Conjunctivitis
-
-
-
-
-
-
-
Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New H
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval
-
-
-
-
-
-
-
Top 6 Healthcare Names To Buy On Weakness - Piper Jaffray
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

